

## TAVR, NOACs, NAFLD, and a Happy New Year

I am pleased to present a very important review, “The implications and requirements of transcatheter aortic valve replacement in low-risk patients,” by E. Murat Tuzcu and Ahmad Edris, from Cleveland Clinic, Abu Dhabi. This article provides important details related to this procedure.

I am also very happy to offer another very valuable review, “Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation,” by Anetta Undas and Leszek Drabik, from Poland. As the editor-in-chief of the Polish Heart Journal, Anetta Undas kindly submitted this review to our journal as part of the effort to encourage scientific collaboration among national journals of the European Society of Cardiology. The authors describe challenges in the use of NOACs in cancer patients with atrial fibrillation and summarized current expert opinions on the subject.

Aslan et al., from Turkey, investigated the effects of melatonin on the protection provided by ischemic postconditioning in ischemia reperfusion-induced infarct size and the roles of uncoupling protein 3, irisin, and nuclear factor-kappa B levels.

“In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features and outcomes,” reported by Paramasivam et al., from India, provides a useful comparison for patients who do not have diabetes mellitus.

Gao et al., from China, describe the effects of losartan, a selective angiotensin II type 1 receptor (AT1R) blocker, on the electrophysiological changes induced by stretch in atrial myocytes associated with blocking of the AT1 receptor, and a beneficial effect in the treatment of atrial fibrillation.

“Assessment of left ventricular function in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease using three-dimensional speckle tracking echocardiography,” by Dong et al., from China, provides very timely details on this condition.

As always, we have several interesting case reports, e-page originals, etc.

I wish our readers a very happy new year with this first issue of our journal for 2020.

**Prof. Dr. Çetin Erol**  
**Editor-in-Chief**  
**Ankara-Turkey**

---

**Address for Correspondence:** Prof. Dr. Çetin Erol, Ankara Üniversitesi Tıp Fakültesi, İbn-i Sina Hastanesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye

Phone: +90 312 310 33 33 /27 79 E-mail: ctnerol@yahoo.com

©Copyright 2020 by Turkish Society of Cardiology - Available online at [www.anatoljcardiol.com](http://www.anatoljcardiol.com)  
DOI:10.14744/AnatolJCardiol.2020.1

